Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01787799




Registration number
NCT01787799
Ethics application status
Date submitted
16/01/2013
Date registered
11/02/2013
Date last updated
16/03/2016

Titles & IDs
Public title
EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
Scientific title
EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)
Secondary ID [1] 0 0
S2072
Universal Trial Number (UTN)
Trial acronym
EVOLVE II QCA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atherosclerotic Lesion(s) 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - SYNERGY

Experimental: SYNERGY Stent System - SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System)


Treatment: Devices: SYNERGY
Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
In-stent Late Loss
Timepoint [1] 0 0
9 month

Eligibility
Key inclusion criteria
- Subject must be at least 18 years of age

- Subject (or legal guardian) understands the trial requirements and the treatment
procedures and provides written informed consent before any trial-specific tests or
procedures are performed

- For subjects less than 20 years of age enrolled at a Japanese site, the subject and
the subject's legal representative must provide written informed consent before any
study-specific tests or procedures are performed

- Subject is eligible for percutaneous coronary intervention (PCI)

- Subject has symptomatic coronary artery disease with objective evidence of ischemia or
silent ischemia

- Subject is an acceptable candidate for coronary artery bypass grafting (CABG)

- Subject is willing to comply with all protocol-required follow-up evaluation

Angiographic Inclusion Criteria (visual estimate)

- Target lesion(s) must be located in a native coronary artery with a visually estimated
reference vessel diameter (RVD) =2.25 mm and =4.0 mm

- Target lesion(s) length must be =34 mm (by visual estimate)

- Target lesion(s) must have visually estimated stenosis =50% and <100% with
thrombolysis in Myocardial Infarction (TIMI) flow >1 and one of the following
(stenosis =70%, abnormal fractional flow reserve (FFR), abnormal stress or imaging
stress test, or elevated biomarkers prior to the procedure)

- Coronary anatomy is likely to allow delivery of a study device to the target
lesions(s)

- The first lesion treated must be successfully pre-dilated/pretreated
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
acute ST elevation MI (STEMI)

- Subject has cardiogenic shock, hemodynamic instability requiring inotropic or
mechanical circulatory support, intractable ventricular arrhythmias, or ongoing
intractable angina

- Subject has received an organ transplant or is on a waiting list for an organ
transplant

- Subject is receiving or scheduled to receive chemotherapy within 30 days before or
after the index procedure

- Planned PCI (including staged procedures) or CABG after the index procedure

- Subject previously treated at any time with intravascular brachytherapy

- Subject has a known allergy to contrast (that cannot be adequately premedicated)
and/or the trial stent system or protocol-required concomitant medications (e.g.,
platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related
compounds, polymer or individual components, all P2Y12 inhibitors (clopidogrel,
ticlopidine, prasugrel, or ticagrelor), or aspirin)

- Subject has one of the following (as assessed prior to the index procedure):

- Other serious medical illness (e.g., cancer, congestive heart failure) with
estimated life expectancy of less than 24 months

- Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)

- Planned procedure that may cause non-compliance with the protocol or confound
data interpretation

- Subject is receiving chronic (=72 hours) anticoagulation therapy (i.e., heparin,
coumadin) for indications other than acute coronary syndrome

- Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3

- Subject has a white blood cell (WBC) count < 3,000 cells/mm3

- Subject has documented or suspected liver disease, including laboratory evidence of
hepatitis

- Subject is on dialysis or has baseline serum creatinine level >2.0 mg/dL (177µmol/L)

- Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
transfusions

- Subject has had a history of cerebrovascular accident (CVA) or transient ischemic
attack (TIA) within the past 6 months

- Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding

- Subject has severe symptomatic heart failure (i.e., New York Heart Association (NYHA)
class IV)

- Subject is participating in another investigational drug or device clinical trial that
has not reached its primary endpoint

- Subject intends to participate in another investigational drug or device clinical
trial within 12 months after the index procedure

- Subject with known intention to procreate within 12 months after the index procedure
(women of child-bearing potential who are sexually active must agree to use a reliable
method of contraception from the time of screening through 12 months after the index
procedure)

- Subject is a woman who is pregnant or nursing (a pregnancy test must be performed
within 7 days prior to the index procedure in women of child-bearing potential)

Angiographic Exclusion Criteria (visual estimate)

Planned treatment of more than 3 lesions

- Planned treatment of lesions in more than 2 major epicardial vessels

- Planned treatment of a single lesion with more than 1 stent

- Subject has 2 target lesions in the same vessel that are separated by less than 15 mm
(by visual estimate)

- Target lesion(s) is located in the left main

- Target lesion(s) is located within 3 mm of the origin of the left anterior descending
(LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate.

- Target lesion(s) is located within a saphenous vein graft or an arterial graft

- Target lesion(s) will be accessed via a saphenous vein graft or arterial graft

- Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide
wire crossing

- Target lesion(s) treated during the index procedure that involves a complex
bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)

- Target lesion(s) is restenotic from a previous stent implantation or study stent would
overlap with a previous stent

- Subject has unprotected left main coronary artery disease (>50% diameter stenosis)

- Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent,
cutting balloon atherectomy) within 24 hours prior to the index procedure

- Thrombus, or possible thrombus, present in the target vessel (by visual estimate)

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2014
Sample size
Target
Accrual to date
Final
100
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Recruitment hospital [1] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [2] 0 0
Monash Medical Centre-Clayton Campus - Clayton
Recruitment hospital [3] 0 0
St Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [4] 0 0
Fremantle Hospital - Fremantle
Recruitment postcode(s) [1] 0 0
4032 - Chermside
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3085 - Fitzroy
Recruitment postcode(s) [4] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
Japan
State/province [1] 0 0
Kanagawa
Country [2] 0 0
New Zealand
State/province [2] 0 0
Auckland
Country [3] 0 0
New Zealand
State/province [3] 0 0
Christchurch
Country [4] 0 0
Singapore
State/province [4] 0 0
Singapore

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boston Scientific Corporation
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Beth Israel Deaconess Medical Center
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Medstar Health Research Institute
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Commercial sector/Industry
Name [3] 0 0
Quintiles, Inc.
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Commercial sector/Industry
Name [4] 0 0
Medidata Solutions
Address [4] 0 0
Country [4] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate 9 month angiographic and intravascular ultrasound
(IVUS) data for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
(SYNERGY Stent System) in the treatment of subjects with atherosclerotic lesion(s) =34 mm in
length (by visual estimate) in native coronary arteries =2.25 mm to =4.0 mm in diameter (by
visual estimate).
Trial website
https://clinicaltrials.gov/ct2/show/NCT01787799
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ian Meredith, Professor
Address 0 0
Monash Medical Centre-Clayton Campus, 246 Clayton Road, 3168 Clayton, Victoria, Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01787799